Calidi Biotherapeutics Inc (AMEX: CLDI) is 17.39% higher on its value in year-to-date trading and has touched a low of $0.73 and a high of $16.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CLDI stock was last observed hovering at around $1.47 in the last trading session, with the day’s loss setting it -0.12%.
Currently trading at $1.35, the stock is -9.34% and -21.74% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.89 million and changing -8.16% at the moment leaves the stock -30.74% off its SMA200. CLDI registered -91.35% loss for a year compared to 6-month gain of -10.95%. The firm has a 50-day simple moving average (SMA 50) of $1.7198 and a 200-day simple moving average (SMA200) of $1.9717.
The stock witnessed a -35.71% loss in the last 1 month and extending the period to 3 months gives it a 25.00%, and is 17.39% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.81% over the week and 12.22% over the month.
Calidi Biotherapeutics Inc (CLDI) has around 41 employees, a market worth around $25.44M and $0.00M in sales. Distance from 52-week low is 84.93% and -91.96% from its 52-week high.
The EPS is expected to grow by 78.64% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
34.0 institutions hold shares in Calidi Biotherapeutics Inc (CLDI), with institutional investors hold 3.31% of the company’s shares. The shares outstanding are 93.11M, and float is at 16.73M with Short Float at 3.96%. Institutions hold 2.71% of the Float.
Calidi Biotherapeutics Inc (CLDI) Insider Activity
The most recent transaction is an insider sale by Camaisa Allan, the company’s CEO and Chairman of the Board. SEC filings show that Camaisa Allan sold 10,000 shares of the company’s common stock on Dec 17 ’24 at a price of $1.62 per share for a total of $16200.0. Following the sale, the insider now owns 66712.0 shares.
